The Latest Breaking News from SPRO

3 Pharma Stocks to Snatch up During Market Dips

The pharmaceutical industry is undergoing rapid growth and expansion, driven by rising medical needs, favorable regulatory measures, and the implementation of pharma 4.0. Hence, investors could snatch up quality pharma stocks Bristol-Myers Squibb (BMY), Spero Therapeutics (SPRO), and OptiNose (OPTN) for steady returns during market dips. Read more.

StockNews.com · May 3, 2024

3 Affordable Pharma Stocks to Buy for Portfolio Gains

The pharmaceutical market is anticipated to grow substantially in the upcoming years, owing to technological innovation and rising demand for personalized medicines. To that end, affordable pharma stocks ACADIA Pharmaceuticals (ACAD), Astellas Pharma (ALPMY), and Spero Therapeutics (SPRO), trading under $20, could be solid buys now. Read on….

StockNews.com · Apr 12, 2024

4 Sky-Rocketing Pharma Stocks to Watch

The pharmaceutical industry is experiencing significant growth due to the rising demand for quality healthcare and high-quality drugs. This surge is further supported by the rapid growth in the global elderly population and the increase in chronic illnesses. Therefore, investors could consider adding pharma stocks Spero Therapeutics (SPRO), Wave Life…

StockNews.com · Feb 27, 2024

FDA Identifies Review Issues For Spero's Tebipenem Application, Shares Plunge

Spero Therapeutics Inc (NASDAQ:SPRO) will defer current commercialization activities for tebipenem HBr based on feedback from a recent Late Cycle Meeting (LCM) with the FDA.  The discussion suggested that the data package may be insufficient to support approval during this review cycle. In evaluating the efficacy of tebipenem HBr in Phase 3 (ADAPT-PO)…

Benzinga · May 3, 2022